TWO YEAR NEURODEVELOPMENTAL OUTCOME OF INFANTS <1350G ENROLLED IN A MULTICENTER COMPARISON TRIAL OF EXOSURF (EXO) AND INFASURF (INFA) FOR THE TREATMENT OF RDS. 1648

The purpose of this study was to evaluate motor, cognitive, and sensory outcomes of infants <1350 grams enrolled in a randomized double-masked comparison trial of two surfactants (EXO vs INFA) for the treatment of RDS. 95 infants (61.0% follow-up) at 5 centers received Bayley mental and motor scales and an expanded neurological examination at 2 years by assessors masked to neonatal treatment status. Table

Table 1

At age 2 years, 91.5% of EXO and 93.3% of INFA were free of any cerebral palsy, 16.7% of EXO and 10.6% of INFA had major cognitive impairment (MDI<70). 33.3% of EXO and 36.2% of INFA were at risk (MDI 70-89) for future disabilities.

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account

Continue with Google

Continue with ORCiD